12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Mon, 01 Jun 2026 06:53:43 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Set-Cookie: UpalLiveSession=eyJpdiI6ImFHbEUwMmpaQUZUK2JDT0FTeFlXU2c9PSIsInZhbHVlIjoiTmxwaEw5bjZ1RXZhVnVvTk12cUV2dEVqdG1YVWhibVpNSkdKRGZxNFBQVDZheFhzTWQ0dE5aNVJrdVJqSE1sTzZmdURsbm1yUnFaek9KeTFcL1RPNEtBPT0iLCJtYWMiOiJhNWFlZjZhNzdjMzFmNzg1ODk3NDA4M2FhMjczYWZjZjkzN2JmOTRkZjNjMWE3ZjE1ODgxZTFmNzkwMTdlNjVlIn0%3D; expires=Thu, 31-May-2029 06:53:43 GMT; Max-Age=94608000; path=/; HttpOnly [7] => X-Frame-Options: SAMEORIGIN [8] => X-Content-Type-Options: nosniff [9] => X-Xss-Protection: 1; mode=block [10] => Referrer-Policy: strict-origin-when-cross-origin [11] => Permissions-Policy: geolocation=(), microphone=(), camera=() [12] => Content-Security-Policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => X-Robots-Tag: noindex, nofollow, nosnippet, noarchive [15] => Strict-Transport-Security: max-age=31536000; includeSubDomains; preload [16] => Expires: Tue, 02 Jun 2026 06:53:43 GMT [17] => Vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=GabkcYraN1iEcJirwpYqgTYAwl%2Bu%2FkvYcl5my4cLiKUnTAw%2FPhR0UpNcGdhywX3ZqOIGVyl7U581%2B0R%2Fwu1bcf3SmVLfd5jLYHUEhLRNLl5lthw%2FcEmpr3bcF3JFZYB1snU%3D"}]} [19] => Cf-Cache-Status: DYNAMIC [20] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [21] => Speculation-Rules: "/cdn-cgi/speculation" [22] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [23] => Server-Timing: cfEdge;dur=11,cfOrigin;dur=716 [24] => CF-RAY: a04c4d84c860192c-LAX [25] => alt-svc: h3=":443"; ma=86400 ) 789

美国吉利德科学公司研发的药物“瑞德西韦”，被认为可望抑制新型冠状病毒感染，中国科学家于周三已在武汉启动临床试验，用于治疗新冠肺炎患者。

媒体报导，主导瑞德西韦研发工作的是来自台湾的女科学家，也就是吉利德制药部门执行副总裁杨台莹。

根据吉利德网站介绍，杨台莹毕业于台湾大学化学系，也拥有南加州大学有机化学博士学位。

她领导吉利德的药物研发与制造部门，负责该公司研发与上市产品。在她的领导下，吉利德研发出全球第一款治疗HIV单锭药物，也将多于25种复方制剂研发成药品。

北京“中日友好医院”的王辰、曹彬团队于周三下午在武汉市金银潭医院宣布启动瑞德西韦治疗2019新型冠状病毒感染临床3期研究，首批试验761位患者。

---

// // // //